Bausch + Lomb stock has rebounded since January, but still offers value, especially with potential takeover interest and a solid balance sheet. BLCO shares trade at a reasonable premium to forward ...

Bausch & Lomb (NYSE:BLCO) may be worth around $28 a share in a potential takeover after reports that the eye care company is exploring a potential sale and is seeing interest from private equity ...

Separate from the refinancing option, Bausch + Lomb is exploring a sale of itself, which could draw interest from private equity buyers. Wed, 18 Sep, 2024 - 10:13 Bausch Health is working with ...

Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. Blackstone, Advent International and TPG are among a long list of private equity firms studying bids for ...

(Bloomberg) -- Bausch Health Cos. is working with Jefferies Financial Group to explore refinancing some of its debt to aid a long-planned spinoff of its stake in the eye-care company Bausch + Lomb, ...

Firm explores completing spinoff of stake in Bausch + Lomb Bausch + Lomb is separately mulling a sale of itself The effort to push out maturities on some of the company’s debt is aimed at vanquishing ...

Laval, Canada-based Bausch Health announced plans in 2020 to separate Bausch + Lomb into an independent, publicly traded company. The intent was to separate the eye care business, which includes ...

Bausch + Lomb Corp. shares rose the most ever following a report that the eye-care company is considering selling itself to disentangle from its debt-laden parent company. The Financial Times reported ...

Bausch + Lomb rose in premarket trading Monday after the Financial Times reported that it is considering selling itself as a way to separate from Bausch Health, its indebted parent company.

(Bloomberg) -- Bausch + Lomb Corp. shares rose the most ever following a report that the eye-care company is considering selling itself to disentangle from its debt-laden parent company.

Eyecare company is working with Goldman Sachs on a deal that would extricate it from its indebted parent, the Financial Times reported The stock of eyecare company Bausch + Lomb Corp. was up 14%on ...